The federal government has contracted to secure an additional 200 million doses of COVID-19 vaccine. President Biden said the country has enough to vaccinate 300 million people by July. (The Washington Post)

Takeda released new data from a Phase III trial showing that maribavir, an antiviral, was successful in treating cytomegalovirus disease. Among 235 patients who received the drug, more than 55% achieved clearance. (Endpoints News)

Data gathering, especially of safety monitoring information, has been limited during the early months of the COVID-19 vaccination effort. Public health officials said the Food and Drug Administration is struggling to get safety data from vaccinations up to date. (The New York Times)

Initial data from South Africa show that people who were previously infected with COVID-19 could be reinfected with the new variant, the World Health Organization said. It added, however, that vaccination may help reduce the severity of the illness. (CNBC Weekly)

A Hunter syndrome drug developed by Denali Therapeutics has shown promise in a small study. Patients using it experienced a reduction of certain carbohydrates linked to the disease, though researchers cautioned more research is needed. (STAT)